QuintilesIMS

New evidence extends validation for quality review

Monday, October 2, 2017

The Good ReseArch for Comparative Effectiveness (GRACE) checklist is a simple 11-item tool that considers the study purpose and provides questions to guide high-level evaluation of methods, data quality and analytics for use in health technology assessments of effectiveness and safety studies. It provides a scoring tool to help evaluate studies in the context of the study goal, and can be used by sophisticated and less experienced users.

[Read More]

Colleen Goggins joins QuintilesIMS Board of Directors

Thursday, July 27, 2017

QuintilesIMS, a provider of information, technology solutions and contract research services to the life sciences industry, announced the appointment of Colleen Goggins to its board of directors, effective today. A senior executive at Johnson & Johnson for more than three decades, Goggins retired in 2011 after serving ten years on J&J’s Executive Committee and as the Worldwide Chairman of its Consumer Group. Under her leadership, the J&J global personal and healthcare portfolio, comprising many of the most recognized consumer brands and medicines in the world, grew to more than $16 billion in annual revenue.

[Read More]

QuintilesIMS to buy DrugDev

Monday, June 26, 2017

QuintilesIMS has reportedly reached an agreement to buy DrugDev, a technology company that has built one of the industry’s largest global investigator networks and data sharing platforms, the latest in series of significant mergers among CROs during recent months.   

[Read More]

Study: New class of oncology therapies provides more options, better outcomes

Monday, June 5, 2017

During the past decade, advances in personalized medicine and immuno-oncology have fueled a major shift in treatment of cancer, according to new research from the QuintilesIMS Institute. Since 2011, 68 novel therapies have been approved across 22 cancer indications globally. These developments have led to more options as well as greater access and improved outcomes for patients—especially for those individuals with metastatic disease.

[Read More]

Report: Spending on medicines totaled $450B in 2016

Thursday, May 4, 2017

In a QuintilesIMS report, various aspects of the market for medicines in the U.S. is highlighed—panning aggregate spending, key medicine categories, volumes, patient cost exposure, as well as an outlook to 2021. The report seeks to provide appropriate context and perspective around the complex factors that drive the level of spending on medicines and their role in our healthcare system.

[Read More]